Novel TLR4 agonist-STAT3 P705 activator

Aluda has a series of NCE small molecules that target STAT3 via a lesser-known variant with specific properties where Aluda believes targeting it may yield a competitive advantage given earlier experience with this target in successful human clinical study.

• TLR4 agonist + STAT3 activators show potential to increase anti-cancer immunity and reduce solid tumors.
• STAT3 Y705p inhibitors as an effective strategy to treat autoimmune diseases and a series of compounds in early development. STAT3 is critical in Th17 cell differentiation and Th17-mediated autoimmunity. Genome-wide association studies have implicated the STAT3 signaling pathway in the development of a range of diseases, such as IBD, lupus and psoriasis. In addition to its effects on immune components, constitutive STAT3 activity in keratinocytes leads to a skin phenotype of psoriasis in mouse models, suggesting that STAT3 links activated keratinocytes and infiltrated leukocytes in psoriasis development.

While STAT3 inhibitors have mainly been evaluated for cancer therapy, the understanding of new variants has provided potential to explore further use in autoimmune disease.

This document was printed from http://www.aludapharm.com/pipeline/stat3.html